Biogen Inc. said on Tuesday it plans to start a global clinical study to assess the safety and benefits of its spinal muscular atrophy drug Spinraza in children who were previously treated with Novartis AG rival therapy Zolgensma.
The study aims at evaluating Spinraza to potentially improve clinical outcomes in some patients who do not respond sufficiently to the gene therapy Zolgensma, the company said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.